Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 3.56
- Piotroski Score 1.00
- Grade Neutral
- Symbol (HCM)
- Company HUTCHMED (China) Limited
- Price $17.98
- Changes Percentage (7.34%)
- Change $1.23
- Day Low $17.80
- Day High $18.44
- Year High $21.92
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $17.50
- High Stock Price Target $17.50
- Low Stock Price Target $17.50
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.60
- Trailing P/E Ratio 29.6
- Forward P/E Ratio 29.6
- P/E Growth 29.6
- Net Income $100.78 M
Income Statement
Quarterly
Annual
Latest News of HCM
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Paycor HCM Getting Closer To Key Technical Measure
Paycor HCM's Relative Strength Rating improved from 68 to 72, signaling market leadership potential. The stock is now extended after a buy point breakout, with earnings growth at 43%. Consider followi...
By Investor's Business Daily | 1 week ago -
Q1 2025 Paycor HCM Inc Earnings Call
Paycor's fiscal first quarter results showcased a 17% revenue growth driven by HCM's unique value proposition. Key highlights include strategic growth initiatives, strong demand indicators, and innova...
By Yahoo! Finance | 1 week ago -
Paycor HCM (PYCR) Q1 2025 Earnings Call Transcript
Paycor HCM reported strong fiscal first quarter results with 17% revenue growth. Key drivers included increased sales productivity, expansion in embedded partnerships, and AI innovation. The company's...
By Yahoo! Finance | 2 weeks ago
